State:
Not Disclosed
Category:
Medical Devices & Manufacturers
Asking Price:
-
Revenue:
-
Company Overview
PRIME exits and American Healthcare Capital are pleased to exclusively represent the Sale of a U.S. patent for a Smoking Cessation therapy product. People who smoke, as well as those who are exposed to second-hand smoke, develop a range of potentially fatal diseases such as a variety of cancers, coronary and cardiovascular diseases leading to heart attacks and stroke, chronic obstructive pulmonary disease (COPD), and immune suppression. These are all due to depleted micronutrients and antioxidants in the body.
Financial Overview
The global cessation products market was estimated at $24 Billion in 2022 and is expected to reach $57 Billion by 2023, showing a CAGR rate of 9.2%.
Asking Price
The Asking Price is to be determined.
Inquire About This Listing:
In order to learn more about our listing, you must:
1. Complete a Buyer Profile:
This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.
YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE.
2. Sign NDA with Listing Code:
To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.
Listing Code:
XYMF1I
Listing Title:
U.S. Patent on Smoking Cessation Therapy Investment and Manufacturing Opportunity
Heading 4
Need to learn more before Signing an NDA- Contact the Lead Advisor For This Mandate
